News
CSLLY
17.56
-1.35%
-0.24
Citi Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 2h ago
Jarden downgrades CSL (CMXHF) to a Hold
TipRanks · 2d ago
Canaccord Genuity downgrades CSL (CMXHF) to a Hold
TipRanks · 2d ago
CSL Seqirus signs long-term PAHO pandemic influenza vaccine supply agreement
PUBT · 2d ago
PAHO SIGNS AGREEMENT TO RESERVE PANDEMIC INFLUENZA VACCINE SUPPLY FOR LATIN AMERICA AND THE CARIBBEAN
Reuters · 2d ago
PAHO: AGREEMENT WITH CSL SEQIRUS AIMED AT SECURING RESERVED SHARE OF PANDEMIC INFLUENZA VACCINES PRODUCTION FOR COUNTRIES IN LATIN AMERICA, CARIBBEAN
Reuters · 2d ago
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 3d ago
CSL (CMXHF) Receives a Buy from Morgans
TipRanks · 3d ago
Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 3d ago
BUZZ-CSL slips 6% as Citi slashes target price, Morningstar urges firm to hire new CEO
Reuters · 3d ago
CSL (CMXHF) Receives a Hold from Bell Potter
TipRanks · 3d ago
CSL downgraded to Neutral from Buy at Citi
TipRanks · 3d ago
Weekly Report: what happened at CSLLY last week (0504-0508)?
Weekly Report · 3d ago
CSL Sees $5 Bln Non-Cash Impairments, Cuts FY26 Outlook; Stock Plunges
NASDAQ · 3d ago
Macquarie Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 3d ago
BRIEF-CSL Expects FY26 Revenue $15.2 Bln, NPATA $3.1 Bln At Constant Currency
Reuters · 4d ago
CSL (CMXHF) Receives a Buy from UBS
TipRanks · 05/08 00:39
Sprout Social Q1 revenue slightly beats estimates
Reuters · 05/07 20:52
Arcturus Therapeutics Q1 revenue drops sharply, net loss widens
Reuters · 05/07 20:09
CSL (CMXHF) Gets a Buy from Morgan Stanley
TipRanks · 05/06 01:35
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.